Abstract 408P
Background
Lung cancer is the leading cause of cancer-related mortality worldwide. Chemotherapy and EGFR TKI combinations may be possible treatment options for patients with NSCLC and activating EGFR mutations. Many clinical trials have shown the potential benefits of these combinations.The addition of chemotherapy to first - and second - generation tyrosine kinase inhibitors significantly improved PFS compared with tyrosine kinase inhibitors monotherapy in treatment- naive patients with EGFR-mutated advanced NSCLC.We undertook the open prospective non-randomized multi -center study in a similar patient population.
Methods
We recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were administrated at days 71-113. Thereafter, gefitinib was re-started on day 135 and continued until disease progression. The primary endpoint was progressive free survival (PFS) time.
Results
From May 2016 to May 2018, 54 patients with advanced (IIIB / IV stages) NSCLC, with activating mutation of the EGFR gene in exon 19 or 21, were included in the study. The objective response rate (ORR) was 55,5%. Serious adverse events were reported by 4 (7,4%) of 54 patients. 2-year PFS in all patients group included in the study at the time of the preliminary analysis was 38.9%, median PFS was 20,0 months (16.0–23,9CI 95%). Median overall survival was not reached.
Conclusions
Integrated chemotherapy with first - and second - generation tyrosine kinase inhibitors is a viable first-line option for patients with non-small-cell lung cancer with EGFR mutation-positive disease, wich can help overcome acquired resistance to tyrosine kinase inhibitors. Tretment benefit of integrated chemotherapy compared with monotherapy of tyrosine kinase inhibitors 1-2 generations is obvious when comparing the results of our study with the data of randomized trials devoted to this problem.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. Laktionov.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session